Hemosiderosis
10
1
1
8
Key Insights
Highlights
Success Rate
89% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
10.0%
1 terminated out of 10 trials
88.9%
+2.4% vs benchmark
40%
4 trials in Phase 3/4
25%
2 of 8 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 8 completed trials
Clinical Trials (10)
Impact of Iron Overload on the Incidence of Liver Complications in Long-Term Survivors (≥10 Years) of Allogeneic Hematopoietic Stem-Cell Transplantation.
Confounder-Corrected Quantitative MRI Biomarker of Hepatic Iron Content
The Prevalence of Nonalcoholic Fatty Liver Disease (NAFLD) Pediatric Patients
Non-invasive Quantification of Liver Iron With MRI
A Study of Long-term Treatment With Deferasirox in Patients With Beta-thalassemia and Transfusional Hemosiderosis
Safety, Tolerability, and Efficacy of Deferasirox in MDS
Efficacy Study in Removing Excess Iron From the Heart
Pharmacogenetic Study in Patients Received Iron Chelating Agent
Extension Study of the Efficacy and Safety of Deferasirox Treatment in Beta-thalassemia Patients With Transfusional Hemosiderosis (Study Amended to 2-year Duration)
Extension Study of Iron Chelation Therapy With Deferasirox in β-thalassemia and Rare Chronic Anemia Patients